Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Serum Protein Assays Validated for Autoanalyzer

By LabMedica International staff writers
Posted on 24 Feb 2011
Fourteen human serum protein assays have been developed and validated for fully automated, user-programmable analyzer. More...


The autoanalyzer is designed to perform potentiometric and photometric assays in serum, plasma, urine, and cerebrospinal fluid, as well as various supernatant sample types.

The assays were developed by scientists at the Foundation for Blood Research, (Scarborough, ME, USA), using de-identified, surplus serum samples stored at -20 °C for less than two months. Samples were selected to encompass a broad range of analyte concentrations and were used for the method comparison studies. The 14 human serum proteins assayed were 1-antitrypsin, 2-macroglobulin, albumin, apolipoproteins AI and B, complement components 3 and 4, haptoglobin, immunoglobulins A, G, and M, orosomucoid, transferrin, and transthyretin. The autoanalyzer used was the versatile Roche cobas c 501, (Roche Diagnostics; Indianapolis, IN, USA), which is from their 6000 series.

Immunoturbidimetric assays for 12 of the 14 proteins were developed using monospecific goat antihuman serum from Midland BioProducts Corporation (Boone, IA, USA). For assaying α-1-antitrypsin and α-2-macroglobulin, goat antihuman serum was obtained from International Immunology Corporation (Murrieta, CA, USA) and DiaSorin (Stillwater, MN, USA), respectively.

The scientists obtained excellent precision at low, normal, and high physiologic concentrations of each protein. Linearity for each method was within 5% of the expected value throughout the calibration range, and method comparison studies to commercial assays were in good agreement. No significant interference was observed from bilirubin, up to 414 mg/L, hemoglobin up to 8.9 g/L, triglyceride, up to 28 g/L, or rheumatoid factor, up to 3,930 IU/mL. Calibration was stable for at least 14 days. The instrument's small reaction cell allowed conservation of nearly 60% of the specimen and reagent volume compared with another system.

The scientists concluded that these newly developed assays provide precise and accurate results with high throughput, but without the associated cost of a dedicated instrument. The study was published on January 19, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:

Foundation for Blood Research
Roche Diagnostics
Midland BioProducts Corporation
International Immunology Corporation
DiaSorin



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.